Trump suspends de minimis exemption for low-value imports
The White House said it's closing what it called a "catastrophic loophole" that shippers use to "evade tariffs and funnel deadly synthetic opioids or below-market products" into the U.S. The order goes into effect Aug. 29.
The exemption had applied to parcels valued at $800 or less, and allowed overseas retailers to ship inexpensive goods to consumers in the U.S. tax-free.
"President Trump is putting an end to the proliferation of shippers worldwide that, among other things, deceptively exploit the de minimis privilege in an effort to evade duties, inspection, and U.S. law," the White House said in a fact sheet outlining the new policy.
Mr. Trump in May ended the de minimis loophole for imports from China and Hong Kong, which had allowed retailers like Shein and Temu to ship ultra low-cost apparel and other goods to U.S.-based consumers at bargain-basement prices. Shipments from China and Hong Kong account for most de minimis shipments to the U.S. according to the White House.
The de minimis provision, which was added to the Tariff Act of 1930 several years after that law's passage, was intended to facilitate trade by eliminating the administrative burden of collecting modest import duties on low-cost goods.
The number of low-value parcels entering the U.S. has surged over the past decade. Between 2015 and 2025, that figure jumped from 134 million shipments per year to nearly 1.4 billion. Customs and Border Patrol processes more than 4 million de minimis shipments to the U.S. daily, according to the White House.
Retailers such as Shein and Temu were forced to scramble when the loophole for imports from China and Hong Kong was suspended earlier this year. China-based Temu halted shipments of Chinese goods to American customers and shifted to only selling products to U.S. shoppers that could be sourced from the company's U.S. warehouses.
Watch: Hawaii Gov. Josh Green gives update on tsunami warning
Forensics expert analysis of Jeffrey Epstein jail video contradicts government's claims
Russia reacts to Trump's new deadline on Ukraine ceasefire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Nvidia, chip stocks jump after Trump says some chipmakers exempt from 100% semiconductor tariff
Chip stocks climbed on Thursday after President Trump said he'll exempt companies from his planned semiconductor tariffs if they have committed to making their chips in the US. 'We'll be putting a tariff of approximately 100% on chips and semiconductors,' Trump said during a press conference at the Oval Office Wednesday afternoon. 'But if you're building in the United States of America, there's no charge.' 'If you've made a commitment to build or if you're in the process of building, as many are, there is no tariff.' Leading AI chipmaker Nvidia (NVDA) stock rose as much as 2.5% Thursday to a fresh intraday high of $183.88 before paring gains midday. Shares of rival Advanced Micro Devices rose more than 6%, while Broadcom (AVGO) and Micron (MU) stocks rose 1% and 2%, respectively. Most of the world's advanced chips are produced by leading contract chip manufacturer TSMC (TSM) in Taiwan, but the company has been building out its capacity in Arizona with a $165 billion investment, exempting it from Trump's tariffs. The company's US-listed shares jumped more than 4% Thursday. Tech companies have rushed to announce investments in their US manufacturing footprint in the hopes of avoiding Trump's trade war wrath. So far, Nvidia has committed to producing $500 billion of AI infrastructure in the US. Micron made a similar $200 billion commitment. Texas Instruments (TXN) has said it's spending $60 billion to bolster its manufacturing capacity in the US. Citi (C) analyst Christopher Danley said the exemptions mean the semiconductor tariff will have 'minimal impact…as US-based semiconductor companies with in-house fabs have operations in the US and fabless companies can commit to using TSMC, Samsung ( GFS (GFS) which have operations in the US.' 'Fabs' refer to factories where chips are produced, and 'fabless' companies outsource production of their chips to contract manufacturers such as TSMC, Samsung, and GFS. Companies with 'in-house fabs' include Intel (INTC), Micron, and Texas Instruments. Nvidia, AMD, Broadcom, and Qualcomm (QCOM) are 'fabless.' Morgan Stanley (MS) analyst Joseph Moore echoed Danley's sentiment, writing in a note to clients Thursday, 'To some degree this outcome would be something of a relief.' 'Yes, 100% tariffs are unpalatable but if companies are given time to restore them, the real tax is just the higher cost of building chips in the United States," he wrote. "The biggest fear was that such a tariff would be implemented immediately.' Still, Bernstein analyst Stacy Rasgon noted that there are questions surrounding how the tariffs would be applied, making it hard to determine its impact. He explained that most semiconductors are imported once they're already inside other products, and the US 'does not import a ton of raw chips" — $45 billion in 2024 — and it's unclear whether duties would just apply to raw semiconductors or also to products containing them. The US Department of Commerce did not immediately respond to Yahoo Finance's request for comment. Further details about the tariffs will be revealed when the agency publishes its findings from an investigation into US semiconductor imports it launched in April under Section 232 of The Trade Expansion Act, which empowers the president to restrict imports of products related to national security. "Trump's public statements often lack detail and nuance, so at this point we do not know exactly how the new rules will be implemented once they go into effect," Rasgon wrote. "We should know more once the actual 232 investigation results are published." Laura Bratton is a reporter for Yahoo Finance. Follow her on Bluesky @ Email her at Sign in to access your portfolio
Yahoo
10 minutes ago
- Yahoo
Water Tower Research Publishes Initiation of Coverage Report on Tian Ruixiang Holdings Limited, 'From Traditional Insurance Broker to Tech-Based Health Insurance Innovator'
Water Tower Research ( has published an Initiation of Coverage Report on Tian Ruixiang Holdings Limited (NASDAQ: TIRX) titled, 'From Traditional Insurance Broker to Tech- Based Health Insurance Innovator'. The report can be accessed here. ST. PETERSBURG, FL, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Water Tower Research ( has published an Initiation of Coverage Report on Tian Ruixiang Holdings Limited (NASDAQ: TIRX) titled, 'From Traditional Insurance Broker to Tech- Based Health Insurance Innovator'. The report can be accessed here. Access to China's growing health insurance market. On June 30, 2025, Chinese insurance broker Tian Ruixiang Holdings Limited completed the acquisition of Ucare, which describes itself as the only cloud-based healthcare value assessment and insurance risk control SaaS platform in China, for total all-stock consideration of $150 million. Ucare's wealth of AI-driven analytics strongly positions TIRX in China's commercial health insurance market, a segment of China's insurance market in which the company has been historically under- represented historically, and which is expected to expand from ~$126 billion today to $280 billion by 2030. Scalable, high-margin SaaS drives reliable revenue in value-based payment & risk analytics. Ucare's cloud-native, multi-tenant platform combined with a network of >4,000 hospital relations, scales with minimal incremental cost, generating gross margins above 90% and recurring subscription-based revenue that complements TIRX's brokerage commission income. This underpins more stable and higher-quality top-line growth as adoption broadens across Ucare's large hospital network. Regulatory and cross-border tailwinds. China's aging demographics, policy reforms to encourage greater healthcare access and affordability, accelerating healthcare digitization adoption (with the domestic healthcare IT market projected to reach ~US$35 billion by 2030 at a CAGR of ~15.6%), present significant tailwinds for TIRX's uniquely enhanced AI- brokerage business model to unlock significant growth potential. Additionally, TIRX has the opportunity to supplement growth with the implementation of its strategy to expand beyond Mainland China recently begun with its move into Hong Kong. Overall, our model projects 35% revenue CAGR to FY28 on a pro forma basis. Valuation. Based on our projections, TIRX's combination with Ucare significantly enhances its revenue growth prospects. Relative to these prospects, TIRX's valuations are below most of our selected comps on both a Price and EV basis. About Water Tower Research Water Tower Research is modernizing investor engagement through research-driven communications. Sound investment research begins with good information. At WTR, we help companies and investors connect by creating expert information flow and strategies that are the foundation of a successful modern investor relations platform. Our analysts and capital markets professionals bring decades of unrivaled Wall Street experience and insight to a new digital world of investor communications and engagement. Our research and investor content is distributed across traditional research aggregators like Bloomberg, FactSet, etc., proprietary direct distribution lists, social media, search engines, and our website. As a result, every institutional and retail investor has equal access to our high-quality company research. Our mission is to help companies take control of their IR program and proactively reach investors while bringing investors a consistent flow of quality information to help them understand our clients' businesses, industries, and the investment opportunities they present. CONTACT: Name: Water Tower Research LLC Email: research@ Job Title: WTR Investor EngagementError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 minutes ago
- Yahoo
E.l.f. Beauty Stock Plunges 13% as Cosmetic Company Pulls Full-Year Forecast
Key Takeaways E.l.f. Beauty shares are down nearly 13% after the company pulled its full-year forecast. CFO Mandy Fields said e.l.f. plans to issue guidance once the U.S.'s approach to trade with China becomes clearer. About 75% of e.l.f. products are manufactured in China and currently subject to a 55% import tax once they reach the U.S., Fields said.E.l.f. Beauty shares buckled amid uncertainty over the future of Chinese tariffs. The cosmetic company's stock was down almost 13% the morning after executives pulled their full-year forecast. E.l.f. Beauty (ELF) expects sales growth of at least 9% year-over-year in the first half of its fiscal year, CFO Mandy Fields said, but the company won't issue a full 2026 forecast until the U.S.'s approach to trade with China becomes clearer. Sales in the quarter ended June 30 were up 5% year-over-year in the U.S. and 9% overall to $353.7 million. The California-based company was monitoring how people react to a $1 price increase enacted Aug. 1, Fields said. 'We're still reading how the consumer will respond to that,' Fields said, according to a transcript made available by AlphaSense. She acknowledged that 'they're continuing to be choiceful with how they're spending.' Beyond charging more, the company aims to offset the cost of tariffs by expanding abroad and optimizing its supply chain. Currently, about 75% of e.l.f. products are made in China—the same portion cited on e.l.f.'s last quarterly earnings conference call. Once products manufactured in China reach the U.S., they are subject to a cumulative import tax of 55%—down from the 170% rate imposed this spring, Fields said. If the current tariff schedule remains in place, e.l.f.'s cost of goods sold would increase by about $50 million annually, she said. (The U.S. and China are trying to reach a trade agreement before Aug. 12, when the White House said a higher tariff will be reinstated.) E.l.f. shares are down about 24% so far this year. Read the original article on Investopedia Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
